-
公开(公告)号：US20080096234A1
公开(公告)日：2008-04-24
申请号：US11795328
申请日：2005-12-15
申请人： Reiji Kannagi , Mineko Izawa , Naoko Kimura , Shunsuke Kurei , Kazue Watanabe
发明人： Reiji Kannagi , Mineko Izawa , Naoko Kimura , Shunsuke Kurei , Kazue Watanabe
IPC分类号： G01N33/574
CPC分类号： C07K16/40 , C07K16/3076 , G01N33/57407 , G01N2333/91194 , G01N2400/02
摘要： [PROBLEMS] To provide examination methods and reagents able to detect efficiently cancer patients and patients at high risk of cancer. [MEANS FOR SOLVING PROBLEMS] Significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, between non-carcinoma tissues and carcinoma tissues or adenoma tissues were discovered. The discovery is evidently applicable to detect carcinomas and adenomas (except colorectal carcinomas and colorectal adenomas) specifically by assaying a certain range of GlcNAc-6-sulfated sugar residue groups in tissues of patients and in fecal samples. Examination of carcinomas and adenomas is possible by the use of antibodies reacting specifically with GlcNAc-6-sulfated sugar residues specifically synthesized by enzymes present in carcinoma and adenoma tissues.
摘要翻译： [问题]提供能够有效检测癌症患者和癌症高危患者的检查方法和试剂。 [解决问题的方法]发现了GlcNAc-6-磺基转移酶同工酶，糖残基硫酸化酶，非癌组织和癌组织或腺瘤组织分布的显着差异。 该发现显然适用于通过测定患者组织和粪便样品中的一定范围的GlcNAc-6-硫酸化糖残基来检测癌和腺瘤（结肠直肠癌和结肠直肠腺癌除外）。 可以通过使用特异性地与存在于癌和腺瘤组织中的酶特异性合成的GlcNAc-6硫酸化糖残基的抗体来检查癌和腺瘤。
-
公开(公告)号：US08580925B2
公开(公告)日：2013-11-12
申请号：US11795328
申请日：2005-12-15
申请人： Reiji Kannagi , Mineko Izawa , Naoko Kimura , Shunsuke Kurei , Kazue Watanabe
发明人： Reiji Kannagi , Mineko Izawa , Naoko Kimura , Shunsuke Kurei , Kazue Watanabe
IPC分类号： C07K16/00
CPC分类号： C07K16/40 , C07K16/3076 , G01N33/57407 , G01N2333/91194 , G01N2400/02
摘要： [PROBLEMS] To provide examination methods and reagents able to detect efficiently cancer patients and patients at high risk of cancer.[MEANS FOR SOLVING PROBLEMS] Significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, between non-carcinoma tissues and carcinoma tissues or adenoma tissues were discovered. The discovery is evidently applicable to detect carcinomas and adenomas (except colorectal carcinomas and colorectal adenomas) specifically by assaying a certain range of GlcNAc-6-sulfated sugar residue groups in tissues of patients and in fecal samples. Examination of carcinomas and adenomas is possible by the use of antibodies reacting specifically with GlcNAc-6-sulfated sugar residues specifically synthesized by enzymes present in carcinoma and adenoma tissues.
摘要翻译： [问题]提供能够有效检测癌症患者和癌症高危患者的检查方法和试剂。 [解决问题的方法]发现了GlcNAc-6-磺基转移酶同工酶，糖残基硫酸化酶，非癌组织和癌组织或腺瘤组织分布的显着差异。 该发现显然适用于通过测定患者组织和粪便样品中的一定范围的GlcNAc-6-硫酸化糖残基来检测癌和腺瘤（结肠直肠癌和结肠直肠腺癌除外）。 可以通过使用特异性地与存在于癌和腺瘤组织中的酶特异性合成的GlcNAc-6硫酸化糖残基的抗体来检查癌和腺瘤。
-
公开(公告)号：US20070196874A1
公开(公告)日：2007-08-23
申请号：US10568544
申请日：2004-07-09
IPC分类号： G01N33/574 , C07K16/30
CPC分类号： G01N33/57419 , G01N2333/91097 , G01N2400/02
摘要： The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. The present inventors discovered that there are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore the inventors applied the discovery to diagnosis and found that colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No. 09961D, Distributor: Becton Dickinson), reacting with GlcNAc-6-sulfated sugar residues, which are produced specifically by the enzyme present in colorectal cancer and colorectal adenoma tissues could be used for the examination of colorectal cancers and colorectal adenomas.
摘要翻译： 本发明提供一种检查结肠直肠癌和结肠直肠腺瘤的方法，其能够以高概率检测结肠直肠癌患者和结肠直肠癌风险高的患者，并且可用于诊断结肠直肠癌和结肠直肠腺瘤，并提供检查试剂 其中。 本发明人发现，GlcNAc-6-磺基转移酶同工酶，糖残基的硫酸化酶在非癌结肠直肠组织，结肠直肠癌组织和结肠直肠腺瘤组织中的分布存在显着差异。 此外，本发明人将该发现应用于诊断，并发现通过测定来自患者或粪便样品的组织中GlcNAc-6-硫酸化糖残基的确定范围来特异性检测结肠直肠癌和腺瘤。 与存在于结肠直肠癌和结肠直肠腺瘤组织中的酶特异性产生的GlcNAc-6硫酸化糖残基反应的MECA-79抗体（Pharmingen，目录号09961D，经销商：Becton Dickinson）可用于检查 结肠直肠癌和结直肠腺瘤。
-
公开(公告)号：US07601348B2
公开(公告)日：2009-10-13
申请号：US10568544
申请日：2004-07-09
IPC分类号： A61K39/395
CPC分类号： G01N33/57419 , G01N2333/91097 , G01N2400/02
摘要： The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. The present inventors discovered that there are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore the inventors applied the discovery to diagnosis and found that colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No. 09961D, Distributor: Becton Dickinson), reacting with GlcNAc-6-sulfated sugar residues, which are produced specifically by the enzyme present in colorectal cancer and colorectal adenoma tissues could be used for the examination of colorectal cancers and colorectal adenomas.
摘要翻译： 本发明提供一种检查结肠直肠癌和结肠直肠腺瘤的方法，其能够以高概率检测结肠直肠癌患者和结肠直肠癌风险高的患者，并且可用于诊断结肠直肠癌和结肠直肠腺瘤，并提供检查试剂 其中。 本发明人发现，GlcNAc-6-磺基转移酶同工酶，糖残基的硫酸化酶在非癌结肠直肠组织，结肠直肠癌组织和结肠直肠腺瘤组织中的分布存在显着差异。 此外，本发明人将该发现应用于诊断，并发现通过测定来自患者或粪便样品的组织中GlcNAc-6-硫酸化糖残基的确定范围来特异性检测结肠直肠癌和腺瘤。 与存在于结肠直肠癌和结肠直肠腺瘤组织中的酶特异性产生的GlcNAc-6硫酸化糖残基反应的MECA-79抗体（Pharmingen，目录号09961D，经销商：Becton Dickinson）可用于检查 结肠直肠癌和结直肠腺瘤。
-
公开(公告)号：US20100015632A1
公开(公告)日：2010-01-21
申请号：US12567944
申请日：2009-09-28
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G01N33/57419 , G01N2333/91097 , G01N2400/02
摘要： The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. There are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore, colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No. 09961D, Distributor: Becton Dickinson), reacting with GlcNAc-6-sulfated sugar residues, which are produced specifically by the enzyme present in colorectal cancer and colorectal adenoma tissues could be used for the examination of colorectal cancers and colorectal adenomas.
摘要翻译： 本发明提供一种检查结肠直肠癌和结肠直肠腺瘤的方法，其能够以高概率检测结肠直肠癌患者和结肠直肠癌风险高的患者，并且可用于诊断结肠直肠癌和结肠直肠腺瘤，并提供检查试剂 其中。 GlcNAc-6-磺基转移酶同工酶，糖残基硫酸化酶，非癌症结肠直肠组织，结肠直肠癌组织和结肠直肠腺瘤组织分布差异均有统计学意义。 此外，通过测定来自患者或粪便样品的组织中的一定范围的GlcNAc-6-硫酸化糖残基来检测结肠直肠癌和腺瘤。 与存在于结肠直肠癌和结肠直肠腺瘤组织中的酶特异性产生的GlcNAc-6硫酸化糖残基反应的MECA-79抗体（Pharmingen，目录号09961D，经销商：Becton Dickinson）可用于检查 结肠直肠癌和结直肠腺瘤。
-
-
-
-
搜索结果
5 条记录 (耗时 0.021 秒)
